OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study.

Abstract

BACKGROUND:

PREDICT was a Canadian, multicenter, prospective, observational study in adults naïve to onabotulinumtoxinA treatment for chronic migraine (CM). We descriptively assess health resource utilization, work productivity, and acute medication use.

METHODS:

OnabotulinumtoxinA (155-195 U) was administered every 12 weeks over 2 years (≤7 treatment cycles). Participants completed a 4-item health resource utilization questionnaire and 6-item Work Productivity and Activity Impairment Questionnaire: Specific Health Problem V2.0. Acute medication use was recorded in daily headache diaries. Treatment-emergent adverse events were recorded throughout the study.

RESULTS:

A total of 197 participants were enrolled, and 184 received ≥1 treatment with onabotulinumtoxinA and were included in the analysis. Between baseline and the final visit, there were decreases in the percentage of participants who reported headache-related healthcare professional visit(s) (96.2% to 76.8%) and those who received headache-related diagnostic testing (37.5% to 9.9%). Reductions from baseline were also observed in the mean number of headache-related visits to an emergency room/urgent care clinic (2.5 to 1.4) and median headache-related hospital admissions (4.0 to 1.0). OnabotulinumtoxinA improved work productivity and reduced the mean (standard deviation) number of hours missed from work over a 7-day period (6.1 [9.7] to 3.0 [6.8]). Mean (standard deviation) acute medication use decreased from baseline (15.2 [7.6] to 9.1 [6.5] days). No new safety signals were identified.

CONCLUSIONS:

Real-world evidence from PREDICT demonstrates that onabotulinumtoxinA treatment for CM in the Canadian population reduces health resource utilization and acute medication use and improves workplace productivity, supporting the long-term benefits of using onabotulinumtoxinA for CM.

• Authors: Werner J Becker, Guy Boudreau, Ian Finkelstein, Corrie Graboski, May Ong, Suzanne Christie, Katherine Sommer, Meetu Bhogal, Goran Davidovic
• Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (Can J Neurol Sci) Vol. 50 Issue 3 Pg. 418-427 (05 2023) ISSN: 0317-1671 [Print] England
• PMID: 35466897 (Publication Type: Observational Study, Multicenter Study, Journal Article)

Chemical References

• Botulinum Toxins, Type A

Topics

• Adult
• Humans
• Botulinum Toxins, Type A (therapeutic use)
• Prospective Studies
• Treatment Outcome
• Chronic Disease
• Canada
• Migraine Disorders (drug therapy, epidemiology)
• Headache (drug therapy)